ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection ##### Up next ![Novo AI's Solution Boosts APRIL International's Efficiency by 400%](https://i0.wp.com/r2.thailandbusinessnews.net/2024/11/APRIL_Asia_Regional_CEO_Romain_Di_Meglio_Novo_AI_Co_founder.jpg?resize=200%2C110&ssl=1 "Novo AI's Solution Boosts APRIL International's Efficiency by 400%") [](https://thailandbusinessnews.net/press-release/novo-ais-solution-boosts-april-internationals-efficiency-by-400/) ###### [Novo AI's Solution Boosts APRIL International's Efficiency by 400%](https://thailandbusinessnews.net/press-release/novo-ais-solution-boosts-april-internationals-efficiency-by-400/) Published on 25 November 2024 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/2516404/ArkBio_Logo.jpg?p=medium600 "logo") SHANGHAI, Nov. 25, 2024 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. This milestone marks a significant advancement in ArkBio’ RSV portfolio, offering a new potential option for preventing RSV infection for vulnerable infants susceptible to RSV. RSV is a globally prevalent and highly contagious RNA virus known for its seasonal epidemic patterns. It is one of the primary pathogens responsible for lower respiratory tract infections in children under five years worldwide and the leading cause of hospitalization among infants under one year of age. The virus spreads mainly through direct contact and airborne droplets, with a high rate of infection especially among children, leading to severe health consequences. High-risk individuals often experience more severe symptoms, frequently requiring hospitalization and, in some cases, facing fatal outcomes. RSV infection is also a significant risk factor for recurrent wheezing and asthma in children. The world faces a heavy healthcare burden and treatment challenges related to RSV infection. AK0610 is a monoclonal antibody targeting the pre-fusion F protein of RSV that was isolated from a recovered infant and engineered. Compared to other RSV-neutralizing antibodies, AK0610 has a unique viral antigen binding epitope and novel mechanism of action. In preclinical studies, AK0610 demonstrated outstanding viral neutralization activity and an extended half-life that offers prolonged protection. It is positioned to become a new generation, long-acting preventive antibody against RSV-induced respiratory infections. The Phase 1 study of AK0610 is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate safety, tolerability, and pharmacokinetics of AK0610 in healthy adults. All 136 participants successfully completed dosing with the maximum administered dose reaching 3000 mg. Most of the study participants have been followed for up to six months with no observed serious adverse events related to the drug and drug exposure reaching the anticipated effective protective concentration, suggesting a desired profile of safety, tolerability, and human pharmacokinetics in healthy subjects. Dr. Jim Wu, CEO of ArkBio, stated, "The successful enrollment and dosing completion of all participants in Phase 1 clinical trial of AK0610 represents a significant step forward for ArkBio in the area of RSV prevention. We extend our sincere gratitude to all participants, physician team, and partners involved in this study for their efforts and contributions. ArkBio is dedicated to drug development for RSV treatment that is represented by our leading therapeutic drug ziresovir as well as RSV prevention. The completion of AK0610’s Phase 1 enrollment and dosing is another significant milestone. Based on the current Phase 1 clinical data, we are encouraged that AK0610 will become a new generation, long-acting monoclonal antibody for RSV prevention. Prevention and treatment of RSV infection complement each other, especially for high-risk populations like infants, the elderly, and immunocompromised patients. This achievement motivates us to continue developing comprehensive and effective prevention and treatment solutions for high-risk and infected patients worldwide, advancing our progress in RSV drug development." About ArkBioArkBio is a global biotech company focusing on discovery and development of innovative drugs for unmet medical needs, especially in the therapeutic areas of respiratory, infectious, and pediatric diseases. Since its inception in 2014, the company has established core technology platforms and built an innovative and highly differentiated R&D pipeline through in-house R&D efforts and external collaborations. Our strong R&D pipeline includes innovative clinical and pre-clinical stage drug candidates with first- or best-in-class potential for global clinical development. As one of the core assets, ziresovir is the first direct-acting RSV antiviral drug that has been developed by ArkBio. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology, Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture investment institutions. For more information about the company, please visit our website: [www.arkbiosciences.com](https://www.arkbiosciences.com/) Investor Inquiries: [Source link ](https://www.prnasia.com/story/archive/4564128_AE64128_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/malaysia-healthcare-connects-cambodian-families-with-leading-malaysian-hospitals-during-first-ever-phnom-penh-expo/) ![MALAYSIA HEALTHCARE CONNECTS CAMBODIAN FAMILIES WITH LEADING MALAYSIAN HOSPITALS DURING FIRST-EVER PHNOM PENH EXPO](https://i0.wp.com/mmx.prnasia.com/media/MS1874351/photo.jpg?resize=260%2C140&ssl=1 "MALAYSIA HEALTHCARE CONNECTS CAMBODIAN FAMILIES WITH LEADING MALAYSIAN HOSPITALS DURING FIRST-EVER PHNOM PENH EXPO") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## MALAYSIA HEALTHCARE CONNECTS CAMBODIAN FAMILIES WITH LEADING MALAYSIAN HOSPITALS DURING FIRST-EVER PHNOM PENH EXPO PHNOM PENH, Cambodia, June 29, 2026 /PRNewswire/ — Malaysia Healthcare Travel Council… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - June 29, 2026 [](https://thailandbusinessnews.net/press-release/ascletis-to-present-28-day-multiple-ascending-dose-study-results-of-oral-small-molecule-glp-1r-agonist-asc30-at-the-61st-european-association-for-the-study-of-diabetes-easd-annual-meeting/) ## Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting – Ascletis to present data from the U.S. Phase Ib clinical study… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - September 2, 2025 [](https://thailandbusinessnews.net/press-release/innovent-biologics-and-lilly-enter-into-commercialization-agreement-for-verzenios-abemaciclib-in-mainland-china/) ## Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ — Innovent Biologics,… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - June 30, 2026 ##### Most Read - [![Visa Unveils Revised Singapore Security Roadmap to Strengthen Trust and Resilience in the AI Era](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/visa-unveils-revised-singapore-security-roadmap-to-strengthen-trust-and-resilience-in-the-ai-era/ "Visa Unveils Revised Singapore Security Roadmap to Strengthen Trust and Resilience in the AI Era") [Visa Unveils Revised Singapore Security Roadmap to Strengthen Trust and Resilience in the AI Era](https://thailandbusinessnews.net/press-release/visa-unveils-revised-singapore-security-roadmap-to-strengthen-trust-and-resilience-in-the-ai-era/ "Visa Unveils Revised Singapore Security Roadmap to Strengthen Trust and Resilience in the AI Era") - [![DETERMINANT UNVEILS FALL/WINTER 2026 COLLECTION WITH A NEW TAKE ON EVERYDAY CASUALWEAR](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/determinant-unveils-fall-winter-2026-collection-with-a-new-take-on-everyday-casualwear/ "DETERMINANT UNVEILS FALL/WINTER 2026 COLLECTION WITH A NEW TAKE ON EVERYDAY CASUALWEAR") [DETERMINANT UNVEILS FALL/WINTER 2026 COLLECTION WITH A NEW TAKE ON EVERYDAY CASUALWEAR](https://thailandbusinessnews.net/press-release/determinant-unveils-fall-winter-2026-collection-with-a-new-take-on-everyday-casualwear/ "DETERMINANT UNVEILS FALL/WINTER 2026 COLLECTION WITH A NEW TAKE ON EVERYDAY CASUALWEAR") - [![Trinasolar Vertex N Modules Selected for 562MWdc Dầu Tiếng 5 Floating Solar Project in Vietnam](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/trinasolar-vertex-n-modules-selected-for-562mwdc-dau-tieng-5-floating-solar-project-in-vietnam/ "Trinasolar Vertex N Modules Selected for 562MWdc Dầu Tiếng 5 Floating Solar Project in Vietnam") [Trinasolar Vertex N Modules Selected for 562MWdc Dầu Tiếng 5 Floating Solar Project in Vietnam](https://thailandbusinessnews.net/press-release/trinasolar-vertex-n-modules-selected-for-562mwdc-dau-tieng-5-floating-solar-project-in-vietnam/ "Trinasolar Vertex N Modules Selected for 562MWdc Dầu Tiếng 5 Floating Solar Project in Vietnam") - [![Agoda Spotlights Asia's Best "Skip-Gen" Destinations for Grandparents and Grandchildren Alike](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/agoda-spotlights-asias-best-skip-gen-destinations-for-grandparents-and-grandchildren-alike/ "Agoda Spotlights Asia's Best "Skip-Gen" Destinations for Grandparents and Grandchildren Alike") [Agoda Spotlights Asia's Best "Skip-Gen" Destinations for Grandparents and Grandchildren Alike](https://thailandbusinessnews.net/press-release/agoda-spotlights-asias-best-skip-gen-destinations-for-grandparents-and-grandchildren-alike/ "Agoda Spotlights Asia's Best "Skip-Gen" Destinations for Grandparents and Grandchildren Alike") - [![Why Hong Kong didn't follow the "doomsday scenarios" Western media had prefabricated](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/why-hong-kong-didnt-follow-the-doomsday-scenarios-western-media-had-prefabricated/ "Why Hong Kong didn't follow the "doomsday scenarios" Western media had prefabricated") [Why Hong Kong didn't follow the "doomsday scenarios" Western media had prefabricated](https://thailandbusinessnews.net/press-release/why-hong-kong-didnt-follow-the-doomsday-scenarios-western-media-had-prefabricated/ "Why Hong Kong didn't follow the "doomsday scenarios" Western media had prefabricated") - [![ThreatBook Accredited by IMDA Singapore for Full Cycle Agentic Cybersecurity Solutions](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/threatbook-accredited-by-imda-singapore-for-full-cycle-agentic-cybersecurity-solutions/ "ThreatBook Accredited by IMDA Singapore for Full Cycle Agentic Cybersecurity Solutions") [ThreatBook Accredited by IMDA Singapore for Full Cycle Agentic Cybersecurity Solutions](https://thailandbusinessnews.net/press-release/threatbook-accredited-by-imda-singapore-for-full-cycle-agentic-cybersecurity-solutions/ "ThreatBook Accredited by IMDA Singapore for Full Cycle Agentic Cybersecurity Solutions") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/activate-expands-down-under-with-first-australian-location-in-melbourne/) ## ACTIVATE EXPANDS DOWN UNDER WITH FIRST AUSTRALIAN LOCATION IN MELBOURNE WINNIPEG, MB, Sept. 10, 2026 /PRNewswire/ — Activate, North America’s… [](https://thailandbusinessnews.net/press-release/elegoo-day-2026-building-a-more-connected-ecosystem-where-ideas-become-real/) ![ELEGOO DAY 2026: Building a More Connected Ecosystem Where Ideas Become Real](https://i0.wp.com/mmx.prnasia.com/media/MS1985399/20260909211259EDT_image_1.jpg?resize=260%2C140&ssl=1 "ELEGOO DAY 2026: Building a More Connected Ecosystem Where Ideas Become Real") ## ELEGOO DAY 2026: Building a More Connected Ecosystem Where Ideas Become Real ELEGOO brings community together with the launch of its annual celebration, featuring… [](https://thailandbusinessnews.net/press-release/sacred-journeys-5-transport-leaders-connect-japans-ancient-pilgrimage-routes-to-offer-a-new-kind-of-travel/) ![Sacred Journeys: 5 Transport Leaders Connect Japan's Ancient Pilgrimage Routes to Offer a New Kind of Travel](https://i0.wp.com/mmx.prnasia.com/media/MS1985603/20260910043620EDT_image_1.jpg?resize=260%2C140&ssl=1 "Sacred Journeys: 5 Transport Leaders Connect Japan's Ancient Pilgrimage Routes to Offer a New Kind of Travel") ## Sacred Journeys: 5 Transport Leaders Connect Japan's Ancient Pilgrimage Routes to Offer a New Kind of Travel JR East, JR Central, JR West, JR Shikoku and JAL join forces… [](https://thailandbusinessnews.net/press-release/rision-magic-pro-now-available-for-pre-order-professional-grade-usb-c-thermal-imaging-in-your-pocket/) ![RISION Magic Pro Now Available for Pre-Order: Professional-Grade USB-C Thermal Imaging in Your Pocket](https://i0.wp.com/mmx.prnasia.com/media/MS1985681/20260910071106EDT_image_1.jpg?resize=260%2C140&ssl=1 "RISION Magic Pro Now Available for Pre-Order: Professional-Grade USB-C Thermal Imaging in Your Pocket") ## RISION Magic Pro Now Available for Pre-Order: Professional-Grade USB-C Thermal Imaging in Your Pocket Featuring AI dual-spectrum fusion, intelligent analysis, and instant reporting, the…